The Impact of Multidisciplinary Team Meetings on the Management of Metastatic Prostate Cancer in a Reference Center

Purpose: Prostate cancer (PC) is the second most common cancer in the male population. Considering its clinical-epidemiological profile, the different scenarios of presentation and the various treatment options, multidisciplinary meetings (MDM) are an inseparable part of therapeutic planning. Despite this, there is a lack of data proving their impact on the outcome of patients with prostate cancer. Methods: Retrospective, single-center cohort evaluating the impact of the Tumor Board (TBD) on several variables related to the oncological outcome of patients with metastatic prostate cancer (MPC). Patients were divided into two periods: (1) 2018 - 2019, before TBD; and (2) 2021 - 2022, after TBD. Demographic, qualitative and quantitative characteristics were assessed. Results: 139 patients were included, 72 in the 2018 - 2019 period and 67 in the 2020 - 2021 period. There was a significant reduction in the time taken to consult clinical oncology (p < 0.05) and to start treatment (p < 0.05). Systemic therapy started predominantly in the castration-sensitive setting (70.2% vs 14.3%; p = 0.000). The TBD promoted a higher quality of treatment, with a greater prescription of Docetaxel and new antiandrogens (95.7% vs 64.3%; p = 0.001) and zoledronic acid in the castration-resistant phase (92.5% vs 79.2%; p = 0.047). The TBD discussion optimized follow-up with dropout in only 7.5% of cases (p = 0.000). Conclusion: TBD has a significant impact on the health care of patients with MPC and should be adopted as routine in services that provide this care.